Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

Por Melzer, N, Meuth, S G
Publicado em 2014

Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis

Por Hahn, S., Trendelenburg, G., Scharf, M., Denno, Y., Brakopp, S., Teegen, B., Probst, C., Wandinger, K. P., Buttmann, M., Haarmann, A., Szabados, F., vom Dahl, M., Kümpfel, T., Eichhorn, P., Gold, H., Paul, F., Jarius, S., Melzer, N., Stöcker, W., Komorowski, L.
Publicado no J Neuroinflammation (2017)